Matinas Biopharma Holdings Inc
MTNB
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.5M
Close$
$0.48
37.9% downside
Current Fair Value
37.9% downsideOvervalued by 37.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.50 Million |
|---|---|
| Enterprise Value | $3.29 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2 |
| Beta | 1.62 |
| Outstanding Shares | 6,406,191 |
Return
| Return on Equity | -371.54% |
|---|---|
| Return on Assets | -191.15% |
| Return on Invested Capital | -185.43% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | -2.89 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.47 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-1.50
Average shareholder expectationRevenue Estimate
$25,000
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-1.50
Average shareholder expectationRevenue Estimate
$25,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.47%▼ 1.67% |
|---|---|
| Total Invested | $177,274▼ 31.89% |
| Investors Holding | 28▼ 1.00% |
ESG Score
No data
About Matinas Biopharma Holdings Inc
CEO: Jerome Jabbour